NASDAQ:ELGX

Endologix (ELGX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.07
$0.08
50-Day Range
$0.02
$0.22
52-Week Range
$0.22
$7.10
Volume
85,372 shs
Average Volume
1.28 million shs
Market Capitalization
$1.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ELGX stock logo

About Endologix Stock (NASDAQ:ELGX)

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

ELGX Stock News Headlines

The Next Step of Their Control Is Here …
Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.
The Next Step of Their Control Is Here …
Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.
See More Headlines
Receive ELGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endologix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2020
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:ELGX
CUSIP
29266S10
Fax
N/A
Employees
528
Year Founded
N/A

Profitability

Net Income
$-64,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$143.37 million
Book Value
$3.56 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.41 million
Optionable
Optionable
Beta
0.73
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. John Onopchenko (Age 60)
    CEO & Director
  • Mr. Vaseem Mahboob (Age 50)
    Chief Financial Officer
  • Dr. Michael V. Chobotov (Age 58)
    Chief Technology Officer
  • Mr. Jeffrey S. Brown
    Chief Operations Officer
  • Mr. Jeremy B. Hayden (Age 49)
    Gen. Counsel

ELGX Stock Analysis - Frequently Asked Questions

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.13. The medical instruments supplier earned $28.51 million during the quarter, compared to analyst estimates of $28.50 million. Endologix had a negative net margin of 44.65% and a negative trailing twelve-month return on equity of 63.96%.

When did Endologix's stock split?

Endologix shares reverse split before market open on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Endologix own?
This page (NASDAQ:ELGX) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners